An In-Depth Overview of Interstitial Lung Diseases for Healthcare Professionals
OthersPage Navigation
Introduction
Interstitial lung diseases (ILDs) represent a heterogeneous group of over 200 chronic lung disorders. They are characterized by inflammation and fibrosis of the pulmonary interstitium, leading to progressive dyspnea and impaired oxygen transport.
Classification and Etiology
ILDs can be classified into idiopathic and secondary forms. Idiopathic pulmonary fibrosis is the most common form, with unknown etiology. Secondary ILDs can be due to connective tissue diseases, occupational and environmental exposures, drug toxicity, or radiation therapy.
Clinical Presentation and Diagnosis
Patients typically present with progressive exertional dyspnea and non-productive cough. Diagnostic evaluation includes high-resolution computed tomography and sometimes lung biopsy. Pulmonary function tests often show a restrictive pattern with reduced diffusion capacity.
Management
Management strategies include treating the underlying cause, supportive care, and in some cases, lung transplantation. Pharmacological therapy includes anti-fibrotic agents, immunosuppressants, and in certain cases, anticoagulants.
Prognosis
Prognosis varies widely, depending on the specific ILD. Generally, idiopathic forms have a poor prognosis, with a median survival of 2-3 years from diagnosis.
Conclusion
Early recognition and appropriate management of ILDs can improve quality of life and potentially slow disease progression. Continuing research is needed to further understand the pathophysiology and to develop more effective treatments.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge